Biogen's latest Alzheimer's drug, Diranersen, has advanced to late-stage trials despite initial disappointing data. This move highlights the company's persistent pursuit of effective treatments for this devastating disease, despite past setbacks. The drug targets tau, a protein associated with Alzheimer's, and while higher doses didn't show significant improvement, the lowest dose demonstrated promising results. This includes reduced tau levels and slowed cognitive decline, which Biogen's head of development, Dr. Priya Singhal, considers compelling evidence for Phase 3 testing. This isn't Biogen's first attempt at Alzheimer's treatment; they've brought two drugs to market, including Aduhelm, which was eventually pulled due to controversy. The company's latest approach, Diranersen, is an antisense oligonucleotide that aims to limit tau production. This strategy is shared by rival Eli Lilly, underscoring the ongoing focus on tau-targeting therapies. The road to an Alzheimer's treatment has been fraught with challenges, but Biogen's determination to explore innovative approaches is commendable. The company's ability to adapt and learn from past failures is crucial for future success in this complex field.
